"
The R&D-Based Pharmaceutical Association Committee (RDPAC) Executive Committee voted to approve the application of Mayoly (Tianjin) Pharmaceutical Co., Ltd. (hereinafter referred to as "Mayoly") to join RDPAC, effective January 1, 2025. With the addition of Mayoly, RDPAC now represents 47 multinational pharmaceutical companies with R&D capabilities. RDPAC remains committed to being a valued partner in delivering the "Healthy China 2030" goals, improving the quality of life of people in China.
 | Desmond Tan |
"I am pleased that Mayoly can join RDPAC and collaborate with our fellow members in supporting ‘Healthy China.’ For more than a century, Mayoly is committed to provide patients and people with the best possible healthcare daily in the areas of gastroenterology and dermocosmetics. Our dedication to patient care aligns perfectly with RDPAC’s vision to support a healthier China through innovation, and we look forward to playing an active role in the activities of RDPAC and to contributing to ‘Healthy China’."
 | Jean-Christophe Pointeau |
"On behalf of RDPAC, I would like to extend a heartfelt welcome to Mayoly as a RDPAC member. RDPAC and its member companies have witnessed and contributed to the development of China's pharmaceutical and healthcare sector, and through having introduced many innovative drugs, they have helped to satisfy the growing demands of Chinese patients. As the Chairman of the RDPAC Executive Committee, I will continue to work with all member companies, including Mayoly, to support China in building a pharmaceutical innovation ecosystem to foster the high-quality industry development, and to contribute to ‘Healthy China’ to improve the health and well-being of people in China."
